Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Analysts Review
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, May 15, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding AbbVie Inc (NYSE: ABBV), Medtronic, Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Zimmer Holdings, Inc. (NYSE: ZMH) and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2471-100free.
AbbVie Inc Analyst Notes
On May 8, 2014, AbbVie Inc (AbbVie) reported that it has submitted marketing authorization applications (MAAs) to the European Medicines Agency (EMA), seeking approval for the investigational, all-oral and interferon-free regimen, to treat adult patients with chronic genotype 1 (GT1) Hepatitis C virus (HCV) infection. According to the Company, MAAs was supported by data from the largest all-oral, interferon-free clinical program in GT1 patients conducted to date, which consist of six Phase III studies including more than 2,300 patients in over 25 countries. Scott Brun, M.D., Vice President of Pharmaceutical Development for AbbVie, said, "These regulatory submissions bring us closer to offering adult genotype 1 chronic hepatitis C patients an all-oral, interferon-free regimen which has the potential to provide a promising advancement for the hepatitis C community in the European Union. This regulatory milestone, on the heels of our submission of a New Drug Application in the U.S., represents an important step for our pipeline." The full analyst notes on AbbVie are available to download free of charge at:
Medtronic, Inc. Analyst Notes
On May 10, 2014, Medtronic, Inc. (Medtronic) announced the results from the first prspective randomized clinical trial which showed that Medtronic implantable cardioverter defibrillators (ICDs) can safely extend the detection times before prompting therapy in secondary prevention patients. Medtronic presented the results of the PainFree SST sub-study at the Heart Rhythm Society's 35th Annual Scientific Sessions, and demonstrated that physicians can choose to program ICDs with delayed detection interval settings without compromising safety for high-risk patients. "ICDs are extremely effective in treating dangerously fast ventricular arrhythmias that can lead to sudden cardiac arrest," said Marshall Stanton, M.D., Vice President and General Manager, Implantable Defibrillator Business, Cardiac Rhythm Disease Management at Medtronic. "Through scientific research and technological advances, Medtronic has successfully reduced the rate of inappropriate shock for ICD patients, helping to clear the way for more patients to benefit from this life-saving technology." The full analyst notes on Medtronic are available to download free of charge at:
Abbott Laboratories Analyst Notes
On May 8, 2014, Abbott Laboratories (Abbott) announced that its vascular devices manufacturing facility in Clonmel, Ireland has been honored with the Shingo Prize - an international award for operational excellence, by the Shingo Institute at the Jon M. Huntsman School of Business at Utah State University. The Company informed that the award recognizes the facility's initiative to develop and maintain constant improvement in achieving operational excellence. "Abbott's dedication to excellence is a driving force across all functions and roles, and is central to our development of innovative business solutions so that we can continue to deliver world-class products to our customers," said Chuck Foltz, Senior Vice President, Vascular, Abbott. "Receiving the top Shingo Prize for our manufacturing facility in Clonmel is a testament to the deep commitment of our employees and to our ongoing focus on serving the people who benefit from our products." The full analyst notes on Abbott are available to download free of charge at:
Zimmer Holdings, Inc. Analyst Notes
On May 7, 2014, Zimmer Holdings, Inc. (Zimmer) reported that Persona®, the Company's personalized knee system, was named as a category finalist for the 2014 Medical Design Excellence Awards (MDEA). The Company informed that the Persona® knee system features advanced orthopaedic technologies such as biologic fixation and long-term stability from its Trabecular Metal™ Technologies, and antioxidant protection from its Vivacit-E® Vitamin E Highly Crosslinked Polyethylene bearing surfaces. Stephen E. White, Senior Vice President and General Manager, Knees, Zimmer, said, "We believe it is recognition of the expertise, effort and energy across the Zimmer Knee team that went into making this product a success for surgeons, institutions and, most importantly, patients. With the Persona® System, Zimmer has truly redefined knee replacement." The full analyst notes on Zimmer are available to download free of charge at:
Arena Pharmaceuticals, Inc. Analyst Notes
On May 9, 2014, Arena Pharmaceuticals, Inc. (Arena) reported that Eisai Inc. (Eisai), who is responsible for the marketing and distribution of BELVIQ in the US under its agreement with Company, plans to increase the sales force for BELVIQ® by 50%. According to the Company, Eisai's proposed sales force expansion to approximately 600, is expected to become effective on July 1, 2014, and enable them to reach approximately 90,000 physicians in the United States. Jack Lief, President and CEO of Arena, said, "With 600 representatives soon to be in the field and increased outreach to consumers about the availability of this treatment option, BELVIQ is well positioned to continue the upward trend in physician and patient adoption." The full analyst notes on Arena are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.